» Articles » PMID: 36437296

A Deep Learning Model Based on Whole Slide Images to Predict Disease-free Survival in Cutaneous Melanoma Patients

Overview
Journal Sci Rep
Specialty Science
Date 2022 Nov 27
PMID 36437296
Authors
Affiliations
Soon will be listed here.
Abstract

The application of deep learning on whole-slide histological images (WSIs) can reveal insights for clinical and basic tumor science investigations. Finding quantitative imaging biomarkers from WSIs directly for the prediction of disease-free survival (DFS) in stage I-III melanoma patients is crucial to optimize patient management. In this study, we designed a deep learning-based model with the aim of learning prognostic biomarkers from WSIs to predict 1-year DFS in cutaneous melanoma patients. First, WSIs referred to a cohort of 43 patients (31 DF cases, 12 non-DF cases) from the Clinical Proteomic Tumor Analysis Consortium Cutaneous Melanoma (CPTAC-CM) public database were firstly annotated by our expert pathologists and then automatically split into crops, which were later employed to train and validate the proposed model using a fivefold cross-validation scheme for 5 rounds. Then, the model was further validated on WSIs related to an independent test, i.e. a validation cohort of 11 melanoma patients (8 DF cases, 3 non-DF cases), whose data were collected from Istituto Tumori 'Giovanni Paolo II' in Bari, Italy. The quantitative imaging biomarkers extracted by the proposed model showed prognostic power, achieving a median AUC value of 69.5% and a median accuracy of 72.7% on the public cohort of patients. These results remained comparable on the validation cohort of patients with an AUC value of 66.7% and an accuracy value of 72.7%, respectively. This work is contributing to the recently undertaken investigation on how treat features extracted from raw WSIs to fulfil prognostic tasks involving melanoma patients. The promising results make this study as a valuable basis for future research investigation on wider cohorts of patients referred to our Institute.

Citing Articles

Clinical Approaches for the Management of Skin Cancer: A Review of Current Progress in Diagnosis, Treatment, and Prognosis for Patients with Melanoma.

Connor C, Carr Q, Sweazy A, McMasters K, Hao H Cancers (Basel). 2025; 17(4).

PMID: 40002300 PMC: 11853469. DOI: 10.3390/cancers17040707.


Self supervised artificial intelligence predicts poor outcome from primary cutaneous squamous cell carcinoma at diagnosis.

Coudray N, Juarez M, Criscito M, Claudio Quiros A, Wilken R, Jackson Cullison S NPJ Digit Med. 2025; 8(1):105.

PMID: 39955424 PMC: 11830021. DOI: 10.1038/s41746-025-01496-3.


Deep learning-based analysis of EGFR mutation prevalence in lung adenocarcinoma H&E whole slide images.

Park J, Lim J, Kim S, Kim C, Choi J, Lim J J Pathol Clin Res. 2024; 10(6):e70004.

PMID: 39358807 PMC: 11446692. DOI: 10.1002/2056-4538.70004.


Transfer learning approach in pre-treatment CT images to predict therapeutic response in advanced malignant pleural mesothelioma.

Fanizzi A, Catino A, Bove S, Comes M, Montrone M, Sicolo A Front Oncol. 2024; 14:1432188.

PMID: 39351354 PMC: 11439621. DOI: 10.3389/fonc.2024.1432188.


A Robust Deep Learning Method with Uncertainty Estimation for the Pathological Classification of Renal Cell Carcinoma Based on CT Images.

Yao N, Hu H, Chen K, Huang H, Zhao C, Guo Y J Imaging Inform Med. 2024; .

PMID: 39313716 DOI: 10.1007/s10278-024-01276-7.


References
1.
Brinker T, Kiehl L, Schmitt M, Jutzi T, Krieghoff-Henning E, Krahl D . Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours. Eur J Cancer. 2021; 154:227-234. DOI: 10.1016/j.ejca.2021.05.026. View

2.
Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P . The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging. 2013; 26(6):1045-57. PMC: 3824915. DOI: 10.1007/s10278-013-9622-7. View

3.
LeCun Y, Bengio Y, Hinton G . Deep learning. Nature. 2015; 521(7553):436-44. DOI: 10.1038/nature14539. View

4.
Hyams D, Cook R, Buzaid A . Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers. J Surg Oncol. 2018; 119(2):175-186. PMC: 6590387. DOI: 10.1002/jso.25319. View

5.
Guida M, Pisconti S, Pisconte S, Colucci G . Metastatic melanoma: the new era of targeted therapy. Expert Opin Ther Targets. 2012; 16 Suppl 2:S61-70. DOI: 10.1517/14728222.2011.645807. View